Retatrutide TRIUMPH-2 Trial Tests Diabetes Weight Loss Limits

A Phase 3 clinical trial of Eli Lilly's retatrutide is examining whether a three-receptor approach can improve weight loss outcomes in adults with type 2 diabetes. The TRIUMPH-2 study enrolled 1,152 adults with overweight or obesity and type 2 diabetes, followed participants for 80 weeks, and published its findings in The Lancet on September 29, 2026.

According to the trial report, retatrutide targets three hormone receptors: GLP-1, GIP, and glucagon. The study tests whether this combined mechanism can address limitations observed with earlier weight loss medications in people with diabetes, a population that has generally experienced smaller reductions in body weight than participants without the condition.

Researchers presented detailed TRIUMPH-2 results, including safety and tolerability findings, at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026. The 80-week, double-blind, parallel-group, placebo-controlled trial was designed to assess treatment effects over an extended period.

Enrollment began on July 11, 2023, and ended on November 1, 2024, according to the study information. The extended observation period allowed researchers to examine whether treatment effects persisted beyond the time when weight loss commonly begins to plateau in trials of GLP-1-based therapies.

Previous research has documented a substantial difference in weight loss between people with and without diabetes. A meta-analysis of 45 studies involving 56,580 patients found that participants without diabetes achieved an average 15.7% reduction in baseline body weight at 12 months with GLP-1 receptor agonists, compared with 5.1% in mixed cohorts of patients with diabetes.

The STEP 2 trial also demonstrated this difference with semaglutide 2.4 mg. Participants with type 2 diabetes lost 9.6% of their body weight over 68 weeks, compared with 3.4% among those receiving a placebo, according to the study figures cited in the TRIUMPH-2 analysis.

Separately, Eli Lilly's SURMOUNT-1 trial reported weight loss of up to 22.5% among participants without diabetes receiving tirzepatide at the 15 mg dose. These earlier results established an important benchmark for subsequent metabolic treatments, although differences in study populations and protocols affect direct comparisons.

The biological challenges associated with type 2 diabetes include insulin resistance, compensatory hyperinsulinemia, and changes in gut hormone activity. The source analysis also identifies impaired glucagon regulation as a factor that may affect appetite signaling and metabolic responses to GLP-1 receptor agonists.

Retatrutide's triple-agonist design adds glucagon receptor activity to GLP-1 and GIP signaling. Researchers are investigating whether this combination can influence appetite, metabolic function, and hepatic glucose production differently from medications that act on one or two receptors.

Earlier evidence came from a Phase 2 trial published in the New England Journal of Medicine in June 2023. That study enrolled 338 adults with overweight or obesity and evaluated escalating doses of retatrutide, primarily in a population without type 2 diabetes. The findings provided evidence of weight loss but did not establish how the treatment would perform in a larger diabetes population.

TRIUMPH-2 also addresses operational challenges specific to diabetes trials. According to the source analysis, researchers must account for hypoglycemia risk, existing glucose-lowering medications, and rescue treatment protocols while preserving the study's blinded design.

Background medications can complicate assessments of a treatment's independent effects on body weight and blood glucose. Patients may use therapies such as metformin, SGLT-2 inhibitors, sulfonylureas, or basal insulin, creating differences that investigators must manage when interpreting clinical outcomes.

The trial's methodology is therefore relevant to the design of future metabolic studies, particularly those evaluating treatments for people with type 2 diabetes. The source analysis identifies background therapy management and recruitment procedures as important operational considerations for subsequent Phase 3 programs.